Sarepta therapeutics initiates screening in emergene, a phase 3 clinical study of srp-9003 for the treatment of limb-girdle muscular dystrophy type 2e/r4

Cambridge, mass.--(business wire)--sarepta therapeutics, inc. (nasdaq:srpt), the leader in precision genetic medicine for rare diseases, today announced that screening is underway in study srp-9003-301. also known as emergene, study 9003-301 is a phase 3, multi-national, open-label study of srp-9003 (bidridistrogene xeboparvovec) for the treatment of limb-girdle muscular dystrophy type 2e (lgmd2e/r4), or beta sarcoglycanopathy. emergene will enroll 15 participants (ambulatory and non-ambulatory.
SRPT Ratings Summary
SRPT Quant Ranking